selected publications
-
Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.
Breast cancer research and treatment.
2022
Academic Article
GET IT
Times cited: 6 - Utility of [18F]-fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from posttreatment change in estrogen receptor-positive breast cancer. Neuro-oncology advances. 2021 Academic Article GET IT
-
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer.
NPJ breast cancer.
2021
Academic Article
GET IT
Times cited: 37 -
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
Breast cancer research and treatment.
2021
Academic Article
GET IT
Times cited: 14 -
Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
2020
GET IT
Times cited: 1 -
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
Breast cancer research and treatment.
2020
Academic Article
GET IT
Times cited: 21 -
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic.
CA: a cancer journal for clinicians.
2020
Academic Article
GET IT
Times cited: 18 -
Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
Fertility and sterility.
2020
Academic Article
GET IT
Times cited: 48 -
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia.
JAMA dermatology.
2019
Academic Article
GET IT
Times cited: 57 -
Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study.
Breast cancer research : BCR.
2019
Academic Article
GET IT
Times cited: 46 -
Palliative hysterectomy for vaginal bleeding from breast cancer metastatic to the uterus.
2018
GET IT
Times cited: 4 -
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017
Academic Article
GET IT
Times cited: 89 -
Facilitating informed decisions about breast cancer screening: development and evaluation of a web-based decision aid for women in their 40s.
BMC medical informatics and decision making.
2017
Academic Article
GET IT
Times cited: 21 -
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
JAMA.
2017
Academic Article
GET IT
Times cited: 123 -
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
NPJ breast cancer.
2016
Academic Article
GET IT
Times cited: 23 -
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016
Academic Article
GET IT
Times cited: 132 -
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.
BMC cancer.
2015
Academic Article
GET IT
Times cited: 61 -
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 106 -
Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy.
Clinical breast cancer.
2015
Academic Article
GET IT
Times cited: 26 -
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.
British journal of cancer.
2014
Academic Article
GET IT
Times cited: 5 -
Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients.
Annals of clinical and translational neurology.
2014
Academic Article
GET IT
Times cited: 27 -
Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
The breast journal.
2014
Academic Article
GET IT
Times cited: 14 -
Impact of oncotype DX recurrence score in the management of breast cancer cases.
Clinical breast cancer.
2013
Academic Article
GET IT
Times cited: 14 -
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.
Annals of oncology : official journal of the European Society for Medical Oncology.
2013
Academic Article
GET IT
Times cited: 78 -
Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.
Arthritis care & research.
2012
Academic Article
GET IT
Times cited: 33 -
A new paradigm for mechanobiological mechanisms in tumor metastasis.
Seminars in cancer biology.
2012
Review
GET IT
Times cited: 56 - Eribulin mesylate in the treatment of metastatic breast cancer. Biologics : targets & therapy. 2012 Academic Article GET IT
-
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Breast cancer research and treatment.
2011
Academic Article
GET IT
Times cited: 30 -
A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women.
Breast cancer research and treatment.
2011
Academic Article
GET IT
Times cited: 29 -
Eribulin mesylate for the treatment of breast cancer.
Expert opinion on pharmacotherapy.
2010
Information Resource
GET IT
Times cited: 19 -
A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.
Breast cancer research and treatment.
2009
Academic Article
GET IT
Times cited: 29 -
Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
Clinical breast cancer.
2008
Review
GET IT
Times cited: 4 -
Breast cancer adjuvant endocrine therapy.
Cancer journal (Sudbury, Mass.).
2007
Review
GET IT
Times cited: 13 -
Aromatase inhibitor withdrawal response in metastatic breast cancer.
2006
GET IT
Times cited: 10 -
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Journal of the National Cancer Institute.
2005
Academic Article
GET IT
Times cited: 72 -
Novel and previously reported single-nucleotide polymorphisms in the human 5-HT(1B) receptor gene: no association with cocaine or alcohol abuse or dependence.
American journal of medical genetics.
2001
Academic Article
GET IT
Times cited: 50